Literature DB >> 18380534

Natriuretic peptides - physiology, pathophysiology and clinical use in heart failure.

J Krupicka1, T Janota, Z Kasalová, J Hradec.   

Abstract

The natriuretic peptides - atrial, brain and C-type - were discovered during the last twenty years. Their effects on cardiovascular, renal, cerebral and other tissues through guanylyl cyclase were uncovered. Over the past decade natriuretic peptides (NPs) became a very useful tool in the management of heart failure patients. Results of many clinical trials have shown that BNP and NT-proBNP are helpful for diagnosis of heart failure. They are also independent markers of prognosis not only in heart failure patients but also in patients with other cardiovascular diseases. Recently published data document the utility of NPs in guiding treatment of heart failure patients. In this article, we focus on basic biochemical and physiological characteristics of NPs as well as on their significance in management of heart failure patients. Some limitations and pitfalls of NPs levels interpretation in diagnosing heart failure are also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18380534     DOI: 10.33549/physiolres.931461

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  11 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 2.  B-type natriuretic peptide-guided treatment for heart failure.

Authors:  Julie McLellan; Carl J Heneghan; Rafael Perera; Alison M Clements; Paul P Glasziou; Karen E Kearley; Nicola Pidduck; Nia W Roberts; Sally Tyndel; F Lucy Wright; Clare Bankhead
Journal:  Cochrane Database Syst Rev       Date:  2016-12-22

Review 3.  Sacubitril/valsartan in heart failure: latest evidence and place in therapy.

Authors:  Edgardo Kaplinsky
Journal:  Ther Adv Chronic Dis       Date:  2016-10-19       Impact factor: 5.091

4.  Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function.

Authors:  Ketul R Chaudhary; Sri Nagarjun Batchu; Dipankar Das; Mavanur R Suresh; John R Falck; Joan P Graves; Darryl C Zeldin; John M Seubert
Journal:  Cardiovasc Res       Date:  2009-04-28       Impact factor: 10.787

5.  Reduction in pulmonary artery pressures with use of sacubitril/valsartan.

Authors:  Vincenzo De Simone; Paola Guarise; Gabriele Zanotto; Giorgio Morando
Journal:  J Cardiol Cases       Date:  2019-08-23

6.  Betaine and secondary events in an acute coronary syndrome cohort.

Authors:  Michael Lever; Peter M George; Jane L Elmslie; Wendy Atkinson; Sandy Slow; Sarah L Molyneux; Richard W Troughton; A Mark Richards; Christopher M Frampton; Stephen T Chambers
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

Review 7.  Neuro-hormonal effects of physical activity in the elderly.

Authors:  Grazia D Femminella; Claudio de Lucia; Paola Iacotucci; Roberto Formisano; Laura Petraglia; Elena Allocca; Enza Ratto; Loreta D'Amico; Carlo Rengo; Gennaro Pagano; Domenico Bonaduce; Giuseppe Rengo; Nicola Ferrara
Journal:  Front Physiol       Date:  2013-12-20       Impact factor: 4.566

Review 8.  Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.

Authors:  Edgardo Kaplinsky
Journal:  J Geriatr Cardiol       Date:  2016-11       Impact factor: 3.327

9.  Serum BNP levels are associated with malignant pericardial effusion.

Authors:  Shemy Carasso; Liza Grosman-Rimon; Ali Nassar; Fabio Kusniec; Diab Ghanim; Gabby Elbaz-Greener; Wadi Kinany; Doron Sudarsky; Evgeni Hazanov; Offer Amir
Journal:  Int J Cardiol Heart Vasc       Date:  2019-04-09

Review 10.  Arterial pulmonary hypertension in noncardiac intensive care unit.

Authors:  Mykola V Tsapenko; Arseniy V Tsapenko; Thomas Bo Comfere; Girish K Mour; Sunil V Mankad; Ognjen Gajic
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.